Fluorine F 18 Fluorthanatrace

RADIATION4 trials

Sponsors

M.D. Anderson Cancer Center, University of Washington

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Breast CarcinomaCholangiocarcinomaFallopian Tube CarcinomaMetastatic Breast CarcinomaOvarian CarcinomaPrimary Peritoneal CarcinomaRecurrent Fallopian Tube Carcinoma

Phase 1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

RecruitingNCT03604315

M.D. Anderson Cancer CenterBreast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma +5

Start: 2018-12-18End: 2027-06-30Target: 300Updated: 2026-04-15

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

RecruitingNCT06502691

University of WashingtonAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma

Start: 2026-02-26End: 2030-12-31Target: 22Updated: 2026-05-19

Phase 2

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Active, not recruitingNCT05226663

M.D. Anderson Cancer CenterBreast Carcinoma

Start: 2023-02-27End: 2026-08-20Target: 36Updated: 2026-06-12

[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

Not yet recruitingNCT07673341

University of WashingtonCholangiocarcinoma

Start: 2026-11-01End: 2028-12-31Target: 22Updated: 2026-06-29